Co-culture and Advanced Maternal Age in PGS Program (CC-PGS)
|ClinicalTrials.gov Identifier: NCT01314846|
Recruitment Status : Terminated (difficulty to include patients)
First Posted : March 15, 2011
Last Update Posted : February 29, 2016
Fertilization and embryo development in vivo occurs in appropriate conditions in the mammalian reproductive tract. However in assisted reproductive technology (ART) embryos and oocytes are exposed to certain factors such as temperature, O2 pressure and pH fluctuations that may affect embryo development and viability in vitro. In Preimplantation Genetic Screening program (PGS) the investigators need to culture the embryos until day 5 so the requirement of culture techniques must be optimal to produce acceptable blastocyst rates. As it has been shown before, embryo culture conditions have the potential to impact biopsied embryos and hence PGS success rates.
Nowadays the coculture system with endometrial cells could be an alternative option to improve the blastocyst rates since some publications have indicated that endometrial cells may provide trace elements and growth factors that are not present in defined culture media and reproduce physiologic conditions. Although the role of coculture in vitro fertilization (IVF) has been controversial, a recent meta-analysis has established the potential benefits of coculture system.
The aim of this study was to compare embryologic and clinical outcomes in terms of blastocyst, implantation and pregnancy rates to evaluate endometrial epithelial cell (EEC) coculture versus sequential culture system in advanced maternal age ( ≥39 years) in the PGS program.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||346 participants|
|Observational Model:||Case Control|
|Official Title:||Co-culture Versus Sequential Culture System in Advanced Maternal Age.|
|Study Start Date :||February 2009|
|Primary Completion Date :||February 2010|
|Study Completion Date :||December 2010|
sequential culture system
- implantation rate [ Time Frame: from February 2009 to December 2010 ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01314846
|Madrid, Spain, 28023|